| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | ML203 | CTRPv2 | pan-cancer | AAC | -0.0011 | 1 |
| mRNA | PFI-1 | GDSC1000 | pan-cancer | AAC | 0.001 | 1 |
| mRNA | CAY10618 | CTRPv2 | pan-cancer | AAC | 0.00097 | 1 |
| mRNA | PD-0332991 | CCLE | pan-cancer | AAC | -0.0013 | 1 |
| mRNA | VX-680 | GDSC1000 | pan-cancer | AAC | -0.0013 | 1 |
| mRNA | PF-184 | CTRPv2 | pan-cancer | AAC | -0.0007 | 1 |
| mRNA | LY-2183240 | CTRPv2 | pan-cancer | AAC | 0.00051 | 1 |
| mRNA | AZD4547 | CTRPv2 | pan-cancer | AAC | -0.00055 | 1 |
| mRNA | Repligen 136 | CTRPv2 | pan-cancer | AAC | 0.0005 | 1 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0005 | 1 |